2021.05.19
I-Mab today announced that an abstract detailing clinical data from its U.S. phase 1 study of uliledlimab in combination with atezolizumab in patients with advanced cancer will be presented at the 2021 ASCO Annual Meeting, taking place June 4-8, 2021.
2021.05.18
I-Mab today announced that the first patient has been dosed in an abbreviated combination clinical study of lemzoparlimab with azacitidine in patients with newly diagnosed AML or MDS in China.
2021.05.13
I-Mab has been selected for inclusion in the MSCI China All Shares Index, following MSCI’s most recent semi-annual review.
2021.04.28
I-Mab today announced that the Company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. SEC on April 28, 2021.
2021.04.26
I-Mab today announced positive topline results from its regional multi-center, randomized, double-blind and placebo-controlled phase 2 study evaluating the efficacy and safety of olamkicept administered intravenously biweekly in patients with active ulcerative colitis.
2021.04.14
I-Mab today announced that its abstract on proprietary and highly differentiated CD73 antibody uliledlimab has been selected for detailed poster presentation at the 2021 ASCO Annual Meeting, taking place virtually June 4-8, 2021.
2021.04.06
Both companies jointly announced that the first patient has been dosed in a phase 1 trial for bispecific antibody TJ-L14B/ABL503.
2021.03.31
I-Mab today announced its participation in the following conferences in April.
2021.03.30
I-Mab and ABL Bio today jointly announced that the U.S. FDA has approved the IND application for initiating phase 1 trial for bispecific antibody TJ-CD4B/ABL111.
2021.03.29
I-Mab today announced financial results for the full year ended December 31, 2020 and provided key business updates.